Generation of murine tumor models refractory to αPD-1/-L1 therapies due to defects in antigen processing/presentation or IFNγ signaling using CRISPR/Cas9.

Generation of murine tumor models refractory to αPD-1/-L1 therapies due to defects in antigen processing/presentation or IFNγ signaling using CRISPR/Cas9.

Immune checkpoint blockade (ICB) targeting the programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) fails to provide clinical benefit for most cancer patients due to primary or acquired resistance. Drivers of ICB resistance include tumor antigen processing/presentation machinery (APM) and...

Full description

Bibliographic Details
Main Authors: Paul L Chariou, Christine M Minnar, Mayank Tandon, Mary R Guest, Raj Chari, Jeffrey Schlom, Sofia R Gameiro
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2024-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0287733&type=printable

Internet

https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0287733&type=printable

Similar Items